Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Arvinas, Inc. before investing.

In this article, we go over a few key elements for understanding Arvinas, Inc.’s stock price such as:

• Arvinas, Inc.’s current stock price and volume
• Why Arvinas, Inc.’s stock price changed recently
• Upgrades and downgrades for ARVN from analysts
• ARVN’s stock price momentum as measured by its relative strength

About Arvinas, Inc. (ARVN)

Before we jump into Arvinas, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Want to learn more about Arvinas, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Arvinas, Inc..

Arvinas, Inc.’s Stock Price as of Market Close

As of June 05, 2026, 4:00 PM, CST, Arvinas, Inc.’s stock price was $7.420.

Arvinas, Inc. is down 4.13% from its previous closing price of $7.740.

During the last market session, Arvinas, Inc.’s stock traded between $7.400 and $7.810. Currently, there are approximately 64.00 million shares outstanding for Arvinas, Inc..

Arvinas, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Arvinas, Inc. Stock Price History

Arvinas, Inc.’s (ARVN) price is currently down 17.37% so far this month.

During the month of June, Arvinas, Inc.’s stock price has reached a high of $9.070 and a low of $7.400.

Over the last year, Arvinas, Inc. has hit prices as high as $14.510 and as low as $6.055. Year to date, Arvinas, Inc.’s stock is down 37.44%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Arvinas, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 05, 2026, there was 1 analyst who downgraded Arvinas, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Arvinas, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Arvinas, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Arvinas, Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Arvinas, Inc. (ARVN) by visiting AAII Stock Evaluator.

Relative Price Strength of Arvinas, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 05, 2026, Arvinas, Inc. has a weighted four-quarter relative price strength of -7.03%, which translates to a Momentum Score of 36 and is considered to be Weak.

Want to learn more about how Arvinas, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Arvinas, Inc. Stock Price: Bottom Line

As of June 5, 2026, Arvinas, Inc.’s stock price is $7.420, which is down 4.13% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Arvinas, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.